Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Inclusion Criteria: * Participants aged ≥18 years of age inclusive at the time of giving informed consent. * Have at least one measurable tumor lesion based on RECIST v1.1. One lesion with prior local treatment (i.e., radiotherapy) can be considered measurable only if a disease progression from prior local treatment was demonstrated in the lesion per RECIST v1.1. * Eastern Cooperative Oncology Group performance status of 0 or 1. * Have a predicted life expectancy ≥3 months. * Have histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors that have progressed after at least one available standard therapy; or for whom the standard therapy is considered to be ineffective, inappropriate or intolerable; or for whom a clinical study of an investigational agent is a recognized standard of care. * Have adequate liver function as defined in the protocol. * Have adequate renal function as defined in the protocol. * Have adequate hematologic function as defined in the protocol. * Have adequate coagulation as defined in the protocol. Exclusion Criteria: * Untreated or symptomatic central nervous system (CNS) metastases and leptomeningeal disease. * Have a primary CNS malignancy. * Have active, or a history of, pneumonitis requiring treatment with steroids, or have active, or a history of, interstitial lung disease. * Have clinically significant pulmonary complications including, but not limited to, chronic obstructive pulmonary disease, restrict…